Edition:
India

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

43.80USD
14 Dec 2018
Change (% chg)

$-0.77 (-1.73%)
Prev Close
$44.57
Open
$44.06
Day's High
$44.12
Day's Low
$43.43
Volume
10,271,221
Avg. Vol
6,526,222
52-wk High
$46.46
52-wk Low
$33.20

Select another date:

Fri, Dec 14 2018

Photo

Pfizer's cut-price version of Avastin wins EU panel greenlight

A panel of European Medicines Agency (EMA) on Friday recommended approval for Pfizer Inc's Zirabev, a cheaper version to Roche Holding AG's leading cancer drug Avastin.

Pfizer's cut-price version of Avastin wins EU panel greenlight

Dec 14 A panel of European Medicines Agency (EMA) on Friday recommended approval for Pfizer Inc's Zirabev, a cheaper version to Roche Holding AG's leading cancer drug Avastin.

Roche buys U.S. biotech Jecure in race for liver disease drugs

ZURICH Swiss drugmaker Roche is buying U.S.-based Jecure Therapeutics, joining Pfizer , Gilead Sciences and Novartis in pursuit of new drugs to treat fatty liver disease.

Roche buys U.S. biotech Jecure in race for liver disease drugs

ZURICH Swiss drugmaker Roche is buying U.S.-based Jecure Therapeutics, joining Pfizer, Gilead Sciences and Novartis in pursuit of new drugs to treat fatty liver disease.

Roche buys U.S. biotech Jecure in race for liver disease drugs

ZURICH, Nov 27 Swiss drugmaker Roche is buying U.S.-based Jecure Therapeutics, joining Pfizer, Gilead Sciences and Novartis in pursuit of new drugs to treat fatty liver disease.

FDA approves new blood cancer treatment from Pfizer

The U.S. Food and Drug Administration on Wednesday approved Pfizer Inc's drug to treat a form of blood cancer in newly diagnosed patients as a combination therapy.

UPDATE 2-FDA approves new blood cancer treatment from Pfizer

Nov 21 The U.S. Food and Drug Administration on Wednesday approved Pfizer Inc's drug to treat a form of blood cancer in newly diagnosed patients as a combination therapy.

FDA approves Pfizer's treatment for rare blood cancer

Nov 21 The U.S. Food and Drug Administration said on Wednesday it approved Pfizer Inc's treatment for a rare form of blood cancer in some adults.

Pfizer to raise U.S. drug prices in January after previously backing down

NEW YORK Pfizer Inc said on Friday that it plans to hike U.S. prices on 41 of its medicines in January, after walking back its previous planned price increases this summer under pressure from President Donald Trump.

UPDATE 2-Pfizer to raise US drug prices in January after previously backing down

NEW YORK, Nov 16 Pfizer Inc said on Friday that it plans to hike U.S. prices on 41 of its medicines in January, after walking back its previous planned price increases this summer under pressure from President Donald Trump.

Select another date: